

PATENT Attorney Docket No. 11004US08/100-224.P1.C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:)
Roger G. Little, II, et al.)) <u>Express Mail No. EV 193996813 US</u>
Serial No.: 09/942,021	Mailing Date: December 23, 2002
Filed: August 27, 2001	RECEIVED
For: THERAPEUTIC USES OF) NEULIVED
BACTERICIDAL/PERMEABILITY INCREASING (BPI) PROTEIN))) JAN 0 2 2003
PRODUCTS	TECH CENTER 1600/2900
Examiner: D. Romeo)
Group Art Unit: 1647))

RESPONSE TO OFFICE ACTION OF NOVEMBER 21, 2002 WITH RESTRICTION REQUIREMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed November 21, 2002, Applicants elect Group III claims. Group III consisted of claims 5, 14, 17, and 27, stated by the Examiner as drawn to a method of inhibiting endothelial cell proliferation by administering a BPI protein product.

Group I consisted of original claims 1, 3, 14, stated by the Examiner as drawn to a method of neutralizing the anticoagulant effect of heparin by administering a BPI protein product; Group II consisted of claims 2, 4, 14, 15, 16, stated by the Examiner as drawn to a method of inhibiting angiogenesis by administering a BPI protein product; Group III consisted of claims 5, 14, 17, 22, stated by the Examiner as drawn to a method of inhibiting endothelial cell proliferation by administering a BPI protein product; Group IV consisted of claims 6,14, 18, stated by the Examiner as drawn to a method of treating endometriosis by administering a

BPI protein product; Group V consisted of claims 7, 14, 19, stated by the Examiner as drawn to a method of contraception by administering a BPI protein product; Group VI consisted of claims 8, 9, 14, 20, 21, stated by the Examiner as drawn to a method of inhibiting tumor cell proliferation by administering a BPI protein product; Group VII consisted of claims 10-13, 14, drawn to a method of treating chronic inflammation by administering a BPI protein product.

Applicants' election of Group III, claims 5, 14, 17 and 27, is hereby made without prejudice to Applicants' right to pursue the non-elected claims in one or more divisional applications.

The Examiner is invited to telephone Applicants' representative if the Examiner believes, for any reason, that personal communication would expedite the prosecution of this application.

Respectfully submitted,

DATED: December 23, 2002

Janet M. McNicholas, Ph.D.

Reg. No. 32,918 James M. Hafertepe Reg. No. 51,219

McAndrews, Held & Malloy, Ltd. 500 West Madison Street, 34th Floor Chicago, Illinois 60661 (312) 775-8000 (Telephone) (312) 775-8100 (Facsimile)



PATENT Attorney Docket No. 11004US08/100-224.P1.C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

7-21-0

In the Application of:)
Roger G. Little, II, et al.	Express Mail No. EV193996813US Mailing Date: December 23, 2002
Serial No.: 09/942,021	
Filed: August 27, 2001))
For: THERAPEUTIC USES OF BACTERICIDAL/ PERMEABILITY INCREASING (BPI) PROTEIN PRODUCTS	RECEIVED JAN 0 2 2003
Examiner: D. Romeo	TECH CENTER 1600/2900
Group Art Unit: 1647	

TRANSMITTAL LETTER

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Transmitted herewith for appropriate action are the following:

- 1. A Response to the Office Action with Restriction Requirement mailed November 21, 2002; and
 - 2. A stamped, self-addressed, return-receipt-requested postcard.

The Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. 13-0017 in the name of McAndrews, Held & Malloy, Ltd.

Respectfully submitted,

DATED: December 23, 2002

anet M. McNicholas, Ph.D.

Reg. No. 32,918 James M. Hafertepe

500 West Madison Street, 34th Floor Chicago, Illinois 60661 (312) 775-8000 (Telephone) (312) 775-8100 (Facsimile)

McAndrews, Held & Malloy, Ltd.

Reg. No. 51,219